How Gilead Profited by Slow-Walking a Promising H.I.V. Therapy

/gilead-hiv-drug-tenofovir.html

  • How Gilead Profited by Slow-Walking a Promising H.I.V. Therapy - The New York Times
    https://www.nytimes.com/2023/07/22/business/gilead-hiv-drug-tenofovir.html

    In 2004, Gilead Sciences decided to stop pursuing a new H.I.V. drug. The public explanation was that it wasn’t sufficiently different from an existing treatment to warrant further development.

    In private, though, something else was at play. Gilead had devised a plan to delay the new drug’s release to maximize profits, even though executives had reason to believe it might turn out to be safer for patients, according to a trove of internal documents made public in litigation against the company.

    Gilead, one of the world’s largest drugmakers, appeared to be embracing a well-worn industry tactic: gaming the U.S. patent system to protect lucrative monopolies on best-selling drugs.

    #crime_légal